Ronster schreef op 26 april 2022 08:06:
Paris, France and Camberley, UK – 26 April 2022 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces an update on its ongoing dispute with the Department of Health and Social Care (“DHSC”).
On 9 April 2021, Novacyt announced it was in dispute with the DHSC regarding its second supply contract, announced on 29 September 2020. On 25 April 2022, the Company was notified that the DHSC has now issued a claim against Primerdesign Ltd and Novacyt S.A. for £134.6m relating to this contract. The claim amount is broadly in line with the disputed Q4 2020 revenue, as previously announced by the Company.
The Company continues to believe it has strong grounds to defend the claim and assert its contractual rights, including in relation to recovering outstanding sums due from the DHSC.
The Company is unable to provide further comment at this time due to the ongoing nature of this claim but will provide further updates as appropriate